<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05014867</url>
  </required_header>
  <id_info>
    <org_study_id>Elbanna_003</org_study_id>
    <nct_id>NCT05014867</nct_id>
  </id_info>
  <brief_title>Comparative Study to Assess the Ongoing Pregnancy Rate for Poor Responders Women Undergoing Different Embryo Transfer Protocols</brief_title>
  <official_title>A Prospective, Four Arms, Open Label, Comparative Study to Assess the Ongoing Pregnancy Rate for Poor Responders Women Undergoing Different Embryo Transfer Protocols</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wael Elbanna Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National research centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wael Elbanna Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Published data on sequential transfer are limited and are not consistent. Also, further&#xD;
      research into methods of risk combination and assessment, would allow us to help our patients&#xD;
      make better-informed decisions about whether or not to proceed with invasive diagnostic tests&#xD;
      as the PGS. So our study aims to describe the ongoing pregnancy rate for poor responders&#xD;
      women undergoing four different embryo transfer protocols among four arms within the study.&#xD;
      Moreover, to describe the miscarriage rate, and the baseline characteristics for the same&#xD;
      population. This clinical study will be conducted in compliance with the clinical study&#xD;
      protocol and applicable regulatory requirements.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to describe the ongoing pregnancy rate for poor responders women undergoing&#xD;
      four different embryo transfer protocols among four arms within the study. Moreover, to&#xD;
      describe the miscarriage rate, and the baseline characteristics for the same population. This&#xD;
      clinical study will be conducted in compliance with the clinical study protocol and&#xD;
      applicable regulatory requirements.&#xD;
&#xD;
      This study is prospective, comparative, open label and multi-center study. The study&#xD;
      participants' relevant medical records will be collected and reviewed after obtaining&#xD;
      informed consent for the participants.&#xD;
&#xD;
      The study materials that will be used will include blood tests, and ultrasound. The study&#xD;
      will involve four study arms:&#xD;
&#xD;
      Arm 1: Poor responders women undergoing frozen sequential embryo transfer on Day 3 and Day 5&#xD;
      Arm 2: Poor responders women undergoing sequential fresh embryo transfer on Day 3 and Day 5&#xD;
      Arm 3: Poor responders women undergoing sequential embryo transfer on Day 3 and Day 5 after&#xD;
      performing PGS Arm 4: Poor responders women undergoing conventional frozen embryo transfer on&#xD;
      Day 5&#xD;
&#xD;
      Primary and secondary key measurements will be used in the study.&#xD;
&#xD;
      The primary measures will include:&#xD;
&#xD;
        -  Presence of intrauterine gestational sac at 12 weeks beyond embryo transfer&#xD;
&#xD;
        -  Presence of fetal heart pulsation at 12 weeks beyond embryo transfer&#xD;
&#xD;
      The secondary key measures will include:&#xD;
&#xD;
        -  Occurance of abortion between week 7 and week 20 of gestation&#xD;
&#xD;
        -  Recording the the baseline characteristics of the study participants&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ongoing pregnancy rate for poor responders women in the four arms</measure>
    <time_frame>Till the end of 12 weeks of gestation</time_frame>
    <description>Recording the following for the four arms of the study:&#xD;
Presence of intrauterine gestational sac at 12 weeks beyond embryo transfer&#xD;
Presence of fetal heart pulsation at 12 weeks beyond embryo transfer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>miscarriage rate for poor responders women in the four arms</measure>
    <time_frame>Till the end of 20 weeks of gestation</time_frame>
    <description>Recording the following for the four arms of the study:&#xD;
- Occurance of abortion between week 7 and week 20 of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The baseline characteristics of the study participants</measure>
    <time_frame>Before study intervention of the four arms (at day 2 in the ovulation induction cycle)</time_frame>
    <description>Recording the following for the four arms of the study:&#xD;
-age , body mass index in kg/m^2</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Embryo Transfer in Poor Responders</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <description>Poor responders women undergoing frozen sequential embryo transfer on Day 3 and Day 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <description>Poor responders women undergoing sequential fresh embryo transfer on Day 3 and Day 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <description>Poor responders women undergoing sequential embryo transfer on Day 3 and Day 5 after performing PGS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <description>Poor responders women undergoing conventional frozen embryo transfer on Day 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embryo transfer method</intervention_name>
    <description>Sequential embryo transfer on day 3 and day 5 in a frozen cycle&#xD;
Sequential embryo transfer on day 3 and day 5 in a fresh cycle&#xD;
Sequential embryo transfer on day 3 and day 5 after performing PGS&#xD;
Conventional Day 5 frozen embryo transfer</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Poor responders women undergoing one of the following:&#xD;
&#xD;
          1. Sequential embryo transfer on day 3 and day 5 in a frozen cycle&#xD;
&#xD;
          2. Sequential embryo transfer on day 3 and day 5 in a fresh cycle&#xD;
&#xD;
          3. Sequential embryo transfer on day 3 and day 5 after performing PGS&#xD;
&#xD;
          4. Conventional Day 5 frozen embryo transfer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The age group of these women is 25-45 years&#xD;
&#xD;
          2. Normal endometrial cavity confirmed by hysteroscopy&#xD;
&#xD;
          3. Poor responders with AMH &lt;1&#xD;
&#xD;
          4. Patients with at least grade 1 days 3 embryo and grade 1 day 5 frozen embryos&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any immunological disorders&#xD;
&#xD;
          2. Patients with uncontrolled systemic diseases&#xD;
&#xD;
          3. Patients with previous uterine surgeries except for Cesarean section&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wael Saad Saad El Banna El Banna, MD</last_name>
    <phone>+2 01227760402</phone>
    <email>dr.wael.ss.elbanna@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manal El-Hinnawi, M.Sc.</last_name>
    <phone>01007970546</phone>
    <email>manalelhinnawi@hotmail.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wael Elbanna Clinic</investigator_affiliation>
    <investigator_full_name>Wael Elbanna</investigator_full_name>
    <investigator_title>Managing director for Wael Elbanna Clinic</investigator_title>
  </responsible_party>
  <keyword>Poor responders</keyword>
  <keyword>PGS</keyword>
  <keyword>Sequential</keyword>
  <keyword>Embryo transfer</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

